Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib cream in facial/neck atopic dermatitis
NCT05127421Phase 2Completed
- Sponsor
- Incyte
- Start
- Nov 2021
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing Ruxolitinib Cream with Vehicle Cream (2 arms). Primary endpoint: Proportion of Participants Achieving ≥75% Improvement in Eczema Area and Severity Index of the Head and Neck Region at 4 weeks. Started Nov 2021; status: completed.
02
Drugs
ruxolitinib cream
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05127421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05127421.